A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474
This study is recruiting at 11 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Squamous Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Moffitt Cancer Center ( Site 0021) · Tampa, FL
Michigan · 1
- VA Ann Arbor Healthcare System ( Site 0019) · Ann Arbor, MI
Missouri · 1
- Washington University School of Medicine ( Site 0024) · St Louis, MO
New Jersey · 1
- Valley Health Systems - Ridgewood Campus ( Site 0010) · Paramus, NJ
New York · 1
- New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001) · Albany, NY
Ohio · 1
- Cleveland Clinic - Ohio ( Site 0016) · Cleveland, OH
Oregon · 1
- Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025) · Corvallis, OR
Tennessee · 1
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000) · Nashville, TN
Texas · 1
- Texas Oncology - Central/South Texas ( Site 8002) · Austin, TX
Virginia · 1
- Virginia Cancer Specialists ( Site 0003) · Fairfax, VA
Washington · 1
- Swedish Medical Center-Swedish Cancer Institute ( Site 0023) · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.